Results 111 to 120 of about 433 (169)

Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling. [PDF]

open access: yesNat Methods
Cheng AP   +46 more
europepmc   +1 more source

Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy. [PDF]

open access: yesJ Immunother Cancer
O'Melia MJ   +14 more
europepmc   +1 more source

Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. [PDF]

open access: yesNeuro Oncol
Ramapriyan R   +33 more
europepmc   +1 more source

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. [PDF]

open access: yesJ Clin Oncol
Luke JJ   +19 more
europepmc   +1 more source

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. [PDF]

open access: yesJ Clin Oncol
Varey AHR   +21 more
europepmc   +1 more source

Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. [PDF]

open access: yesClin Cancer Res
Ventin M   +15 more
europepmc   +1 more source

Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma. [PDF]

open access: yesInt J Radiat Oncol Biol Phys
Wisdom AJ   +7 more
europepmc   +1 more source

Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. [PDF]

open access: yesFront Immunol
Karapetyan L   +29 more
europepmc   +1 more source

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. [PDF]

open access: yesClin Cancer Res
Tarhini AA   +15 more
europepmc   +1 more source

Marcellus of Ankyra

open access: yes
Peter Gemeinhardt
core   +1 more source

Home - About - Disclaimer - Privacy